The biopharmaceutical (biopharma) sector has seen significant activity since the start of 2024. Following a challenging year in 2023, the early days of 2024 have been marked by an increase in initial public offerings (IPOs), a surge in venture capital investment, and legislative developments that support U.S. biopharma growth. Since the start of 2024, 4 biopharma companies have held IPOs, and another 3 have filed for their public debuts. This marks a stark contrast to 2023 when only 4 companies held IPOs in Q1. In addition, out of the 18 biopharma IPOs in 2023, 55% were less than $100 million in proceeds. All 4 IPOs in 2024 have exceeded that amount. The current increase in IPO activity suggests a potential sector recovery and signals growing investor interest.
Read the full article: 2024’s Potential Biopharma Boom: Reshaping Healthcare amid Investment and Legislative Shifts //
Source: https://www.chartis.com/insights/2024s-potential-biopharma-boom-reshaping-healthcare-amid-investment-and-legislative-shifts